John Barkett

1 week ago | ajmc.com | Julia Bonavitacola |John Barkett

John Barkett, MBA, managing director in Berkeley Research Group's Healthcare Transactions and Strategy practice, discussed the reasons why Congress is unlikely to codify the recent executive order from the Trump administration that aims to reduce drug prices, including the possibility of disincentivizing innovation. This transcript has been lightly edited for clarity; captions are auto-generated. TranscriptWill Congress take action to codify this executive order?

2 weeks ago | ajmc.com | Julia Bonavitacola |John Barkett

John Barkett, MBA, managing director in Berkeley Research Group's Healthcare Transactions and Strategy practice, explained that the effects on both people on Medicare and pharmaceutical companies will be minimal for a couple of years until the executive order—signed by the Trump administration on May 12 with the aim of lowering drug prices—can be properly enacted. This transcript has been lightly edited for clarity; captions are auto-generated.

2 weeks ago | ajmc.com | Julia Bonavitacola |John Barkett

John Barkett, MBA, managing director in Berkeley Research Group's Healthcare Transactions and Strategy practice, reiterated that the executive order that President Donald Trump signed on May 12 to lower drug costs could be met with legal challenges from the drug industry among others. This transcript has been lightly edited for clarity; captions are auto-generated. TranscriptWhat can we expect when it comes to legal challenges to this executive order?

2 weeks ago | ajmc.com | Julia Bonavitacola |John Barkett

John Barkett, MBA, managing director in Berkeley Research Group's Healthcare Transactions and Strategy practice, explained how the current executive order, signed by President Donald Trump on May 12, is different than a previous attempt at establishing "most favored nation" pricing in 2020. TranscriptHow is this executive order different than other attempts at "most favored nation" pricing?

3 weeks ago | ajmc.com | Julia Bonavitacola |John Barkett

John Barkett, MBA, managing director in BRG's Healthcare Transactions and Strategy practice, detailed how the executive order that was signed by President Donald Trump on May 12 will attempt to impose "most favored nation" pricing for medication in the US. TranscriptCan you explain what the recent executive order entails when it comes to drug pricing? The executive order has just a couple of sections in it and I'm going to start with the one that I think is the biggest news here.